North America Synthetic Opioids Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Synthetic Opioids and Semi-Synthetic Opioids), By Application (Pain Management, and De-Addiction), and North America Synthetic Opioids Market Insights, Industry Trend, Forecasts to 2035

North America Synthetic Opioids Market Insights Forecasts to 2035

• The North America Synthetic Opioids Market Size Was Estimated at USD 92.30 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of Around 1.93% from 2025 to 2035
• The North America Synthetic Opioids Market Size is Expected to Reach USD 113.86 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, The North America Synthetic Opioids Market Size is anticipated to Reach USD 113.86 Billion by 2035, Growing at a CAGR of 1.93% from 2025 to 2035. Abuse-deterrent formulations, sophisticated drug delivery systems, the growth of de-addiction programs, advancements in chronic pain management, and strategic partnerships between pharmaceutical companies and healthcare providers are some of the lucrative opportunities presented by the North America synthetic opioids market.  

Market Overview

The North America Synthetic Opioids Market Size includes the local industry that develops, produces, distributes, and regulates synthetic opioid drugs, such as meperidine, methadone, and fentanyl. These substances are frequently used in the treatment of opioid use disorder and pain management due to they are chemically produced to resemble the analgesic properties of natural opioids. Applications from hospitals, retail pharmacies, and rehabilitation facilities are included in the North America synthetic opioids market. The industry is anticipated to expand as more government agencies introduce innovative strategies to stop the synthetic opioid issue in the region. New developments in pain management and misuse prevention have fueled the rise of the North America synthetic opioids market, which has a wide pipeline at every stage of development. Increased prevalence of chronic pain, growing de-addiction programs, and changing public health regulations are the main factors driving the growth in the North America synthetic opioids market. 

Report Coverage

This research report categorizes the market for North America synthetic opioids market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the North America synthetic opioids market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the North America synthetic opioids market. 

Driving Factors

The market for synthetic opioids in North America is fueled by several important variables that together improve its growth trajectory. In addition to addressing safety and regulatory concerns, a strong medication research pipeline and growing awareness of opioid substitutes encourage market expansion. Long-acting pain management treatments are in greater demand due to the aging population. Technological developments in medication delivery systems, like transdermal patches and formulations with prolonged release, also enhance therapeutic results and patient compliance.

Restraining Factors

Strict regulatory frameworks, the possibility of abuse and addiction, public health issues, restricted payment policies, and the growing cultural opposition to opioid-based pain relief options are the main factors restricting the North America synthetic opioids market.

Market Segmentation

The North America synthetic opioids market share is classified into product type and application.  

• The synthetic opioids segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

The North America synthetic opioids market is segmented by product type into synthetic opioids and semi-synthetic opioids. Among these, the synthetic opioids segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The most effective treatment for moderate to severe cancer-related pain is frequently said to be synthetic opioids. The ongoing creation of synthetic versions intended to lower the risk of addiction while maintaining sufficient clinical efficacy is another factor propelling this segment's expansion.

• The pain management segment held a largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The North America synthetic opioids market is segmented by application into pain management and de-addiction. Among these, the pain management segment held a largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The debilitating disorders of arthritis, lower back pain, and neuropathy, along with the aging of the North America population, serve as the guiding principles for the Pain Management section. Chronic pain severely impairs a patient's quality of life and productivity, which in turn leads to a rise in the use of opioids, both synthetic and prescription, in multimodal pain management regimens.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the North America synthetic opioids market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies    

• AbbVie Inc.
• AstraZeneca Plc.
• Purdue Pharma L.P.
• Endo Pharmaceuticals Inc.
• Hikma Pharmaceuticals PLC
• Mallinckrodt Pharmaceuticals
• Johnson & Johnson Services, Inc.
• Sun Pharmaceutical Industries Ltd
• Teva Pharmaceutical Industries Ltd.
• Others

Key Target Audience 

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In May 2025, A next-generation extended-release synthetic opioid formulation that deters abuse was launched to the U.S. market, according to a statement from Johnson & Johnson. This medication seeks to lessen abuse while preserving its therapeutic benefits for people with chronic pain.

• In March 2025, Purdue Pharma and a biotechnology company collaborated strategically to use targeted receptor modulation technologies to jointly create new synthetic opioid drugs that have a decreased propensity for addiction.

Market Segment

This study forecasts revenue at North America, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the North America synthetic opioids market based on the below-mentioned segments:

North America Synthetic Opioids Market, By Product Type

• Synthetic Opioids
• Semi-Synthetic Opioids

North America Synthetic Opioids Market, By Application

• Pain Management
• De-Addiction